ATLANTA, Nov. 4, 2011 /PRNewswire/ -- UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is marking the 2011 American College of Rheumatology (ACR) meeting by reinforcing its commitment to people living with rheumatoid arthritis (RA) and their healthcare providers. At this year's ACR meeting, UCB is proud to sponsor several key sets of data with new findings on patient-reported quality of life measures, including work and household productivity, as well as other clinical response measures.
"The annual ACR meeting is an excellent opportunity to demonstrate UCB's commitment to rheumatologists and their patients," said Neil McFarlane, Vice President, Immunology Business Unit, UCB, Inc. "Through our body of data at this year's meeting, it is our goal to engage in meaningful dialogue regarding optimal treatment for rheumatoid arthritis."
UCB will not have a promotional booth at the meeting this year, but will staff a medical booth to respond to questions from health care providers.
An Enduring Passion for Patient Care
UCB continues to demonstrate its aspiration of being the patient-centric global biopharmaceutical leader that transforms the lives of people living with severe diseases through scientific research, advocacy and programming. The company provides financial support for important professional and patient programs, including:
Within Our Reach: Finding a Cure for Rheumatoid Arthritis Campaign: UCB is a Pinnacle donor of the $30-plus million ACR Research and Education Foundation (REF) campaign to fund a multi-year research initiative to accelerate high-risk, high-reward research in rheumatoid arthritis not normally funded by the National Institutes of Health or other peer reviewed funding sources. Investigator-initiated and pilot grants are awarded to projects that address basic,
Copyright©2010 PR Newswire.
All rights reserved